MicroPort® Wewin Receives CE Mark for its 2019-nCoV PCR Test Kit

Shanghai, China, 03 August 2021 — MicroPort® Wewin Diagnostics Co., Ltd (MicroPort® Wewin) recently received the CE mark for its self-developed real-time PCR test, SARS-CoV-2 Nucleic Acid Test Kit (PCR Test Kit).

The PCR Test Kit developed by MicroPort® Wewin is used for in vitro qualitative detection of 2019-nCoV nucleic acids in nasal and pharyngeal swab samples from suspected cases and cluster cases of COVID-19, as well as people who require a diagnosis or differential diagnosis of COVID-19. The PCR test kit is based on real-time RT-PCR technology, which provides a reliable diagnostic solution for medical professionals thanks to its high sensitivity, high specificity, anti-carry-over contamination system , and easy monitoring over the entire testing process.

Obtaining the CE Mark for the PCR Test Kit represents the EU market’s recognition of the MicroPort® Weiwin product and lays a solid foundation for extending the reach of MicroPort® Weiwin’s products in the EU and internationally.

The novel coronavirus disease (COVID-19) pandemic is a global pandemic caused by the infection of 2019-nCoV, a newly discovered coronavirus. As of July 26, 2021, more than 194 million confirmed cases of COVID-19 (including more than 4,158,000 deaths) have been reported in more than 200 countries and regions worldwide, making it one of the largest pandemics in human history.

About MicroPort® Wewin

MicroPort® Wewin Diagnostics Co., Ltd (MicroPort® Wewin) is a subsidiary of MicroPort® Scientific Corporation (00853.HK). Founded in March 2021, MicroPort® Wewin is a high-tech diagnostic solution provider with integrated R&D, manufacturing and marketing capability. In the future, the company will continue to adhere to our core belief that, ‘The Patient Always Comes First’, invest more resources in research and development, and remain committed to building new diagnostic technology platforms, providing patients and healthcare practitioners with high quality in vitro diagnosis solutions.